Literature DB >> 9925665

Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells.

P W Baker1, K A Rye, J R Gamble, M A Vadas, P J Barter.   

Abstract

Previous studies have shown that both high density lipoproteins (HDL) isolated from human plasma and reconstituted HDL (rHDL) are effective inhibitors of adhesion molecule expression in human endothelial cells. In this study rHDL have been used to investigate whether HDL particle shape, size, apolipoprotein composition or lipid composition are important determinants of the ability of HDL to inhibit the TNF-alpha induced expression of vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs). On the basis of these studies it is possible to draw several firm conclusions. i) Neither phospholipid-containing vesicles nor lipid-free apolipoprotein (apo) A-I inhibit VCAM-1 expression in HUVECs. ii) Simple discoidal complexes containing only phospholipid and apoA-I (discoidal (A-I)rHDL) are sufficient to inhibit the TNF-alpha-induced expression of VCAM-1 in HUVECs. iii) Spherical apoA-I-containing rHDL (spherical (A-I)rHDL) are superior to discoidal (A-I)rHDL as inhibitors. iv) The particle size of spherical (A-I)rHDL has no influence on the inhibition. v) Spherical rHDL that contain apoA-I are superior as inhibitors of VCAM-1 to those containing apoA-II when the rHDL preparations are equated for apolipoprotein molarity. However, when compared at equivalent particle molarities, this difference is no longer apparent. vi) Replacement of cholesteryl esters with triglyceride in the core of spherical (A-I)rHDL has no effect on the ability of these particles to inhibit VCAM-1 expression. From these results it is tempting to speculate that variations in inhibitory activity may contribute to the variations observed in the anti-atherogenicity of different HDL subpopulations.-Baker, P. W., K-A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9925665

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  34 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

Authors:  Wilissa D'Souza; John A Stonik; Andrew Murphy; Steven J Demosky; Amar A Sethi; Xiao L Moore; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

Review 3.  New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Authors:  Philip J Barter; Rajesh Puranik; Kerry-Anne Rye
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 4.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 5.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

6.  Low high-density lipoprotein cholesterol and particle concentrations are associated with greater levels of endothelial activation markers in Multi-Ethnic Study of Atherosclerosis participants.

Authors:  Brian T Steffen; Suzette J Bielinski; Paul A Decker; Cecilia Berardi; Nicholas B Larson; James S Pankow; Erin D Michos; Naomi Q Hanson; David M Herrington; Michael Y Tsai
Journal:  J Clin Lipidol       Date:  2017-06-13       Impact factor: 4.766

7.  Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium.

Authors:  H M Dansky; S A Charlton; C B Barlow; M Tamminen; J D Smith; J S Frank; J L Breslow
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

8.  Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice.

Authors:  Xinbo Zhang; Xuewei Zhu; Baosheng Chen
Journal:  J Lipid Res       Date:  2010-09-03       Impact factor: 5.922

9.  Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.

Authors:  Kaushal S Gandhi; Fiona C McKay; Eve Diefenbach; Ben Crossett; Stephen D Schibeci; Robert N Heard; Graeme J Stewart; David R Booth; Jonathan W Arthur
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

10.  High density lipoproteins-based therapies for cardiovascular disease.

Authors:  Xuan Gao; Shujun Yuan
Journal:  J Cardiovasc Dis Res       Date:  2010-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.